Edition:
United Kingdom

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

22.90USD
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
$22.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
98,821
52-wk High
$33.21
52-wk Low
$20.20

Select another date:

Tue, Oct 24 2017

BRIEF-Aclaris Therapeutics wins patent in Japan for treating hair loss

* Aclaris Therapeutics announces the allowance of a U.S. patent application and issuance of a Japanese patent covering tofacitinib for treating hair loss disorders Source text for Eikon: Further company coverage:

BRIEF-Deerfield Mgmt reports 5.90 pct passive stake in Aclaris Therapeutics

* Deerfield Mgmt, L.P. reports 5.90 pct passive stake in Aclaris Therapeutics Inc as of Sept 29 - SEC filing Source text: (http://bit.ly/2wKeWrl) Further company coverage:

BRIEF-Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis

* Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis

BRIEF-Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders

* Aclaris Therapeutics announces issuance of two U.S. Patents covering JAK inhibitors for treating hair loss disorders Source text for Eikon: Further company coverage:

BRIEF-Vivo Ventures VII LLC reports 9.5 pct stake in Aclaris Therapeutics

* Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing

BRIEF-Aclaris announces pricing of public offering of common stock

* Aclaris announces pricing of public offering of common stock

BRIEF-Aclaris Therapeutics posts Q2 loss per share $‍0.56​

* Aclaris Therapeutics reports second quarter 2017 financial results

BRIEF-Aclaris Therapeutics has submitted a marketing authorization application with medicines product agency in Sweden

* Has submitted a marketing authorization application with medicines product agency in Sweden

BRIEF-Aclaris Therapeutics submits investigational new drug application for ATI-50002

* Aclaris Therapeutics submits investigational new drug application for ATI-50002 to treat Alopecia Areata

Select another date: